Junji Tsurutani

Researcher Name Resolver ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 26

Top Topics

Liver Metastases

Epidermal Growth Factor Receptor

Metastatic Breast Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Breast cancer (Tokyo, Japan)

Current medical research and opinion

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Naoki Miyazaki, Toshiki Iwasaki, Hitomi Sakai, Rurina Watanuki, Yoshinori Tanizawa, Zhihong Cai, Tsutomu Kawaguchi, Junji Tsurutani, Kengo Nagashima
Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis. Current medical research and opinion 40 (5) (2024)
Toshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, Naoki Niikura, Yeon Hee Park, Keun Seok Lee, Yee Soo Chae, Binghe Xu, Xiaojia Wang, Seock-Ah Im, Wei Li, Yen-Shen Lu, Cecilia Orbegoso Aguilar, Soichiro Nishijima, Yuji Nishiyama, Masahiro Sugihara, Shanu Modi, Junji Tsurutani
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast cancer (Tokyo, Japan) (2024)
Naoki Miyazaki, Toshiki Iwasaki, Hitomi Sakai, Rurina Watanuki, Yoshinori Tanizawa, Zhihong Cai, Tsutomu Kawaguchi, Junji Tsurutani, Kengo Nagashima
Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis. Current medical research and opinion (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Toshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, Naoki Niikura, Yeon Hee Park, Keun Seok Lee, Yee Soo Chae, Binghe Xu, Xiaojia Wang, Seock-Ah Im, Wei Li, Yen-Shen Lu, Cecilia Orbegoso Aguilar, Soichiro Nishijima, Yuji Nishiyama, Masahiro Sugihara, Shanu Modi, Junji Tsurutani
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast cancer (Tokyo, Japan) 31 (5) (2024)
Aditya Bardia, Komal L Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis, Shu-Sen Wang, Noelia Martínez Jañez, Giuliano Borges, David W Cescon, Masaya Hattori, Yen-Shen Lu, Erika Paige Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin M Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M Fairhurst, Sabrina Khan, Neelima Denduluri, Hope S Rugo, Binghe Xu, Barbara Pistilli, null null
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Toshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, Naoki Niikura, Yeon Hee Park, Keun Seok Lee, Yee Soo Chae, Binghe Xu, Xiaojia Wang, Seock-Ah Im, Wei Li, Yen-Shen Lu, Cecilia Orbegoso Aguilar, Soichiro Nishijima, Yuji Nishiyama, Masahiro Sugihara, Shanu Modi, Junji Tsurutani
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast cancer (Tokyo, Japan) 31 (5) (2024)
Naoki Miyazaki, Toshiki Iwasaki, Hitomi Sakai, Rurina Watanuki, Yoshinori Tanizawa, Zhihong Cai, Tsutomu Kawaguchi, Junji Tsurutani, Kengo Nagashima
Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis. Current medical research and opinion 40 (5) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Naoki Miyazaki, Toshiki Iwasaki, Hitomi Sakai, Rurina Watanuki, Yoshinori Tanizawa, Zhihong Cai, Tsutomu Kawaguchi, Junji Tsurutani, Kengo Nagashima
Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis. Current medical research and opinion 40 (5) (2024)
Toshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, Naoki Niikura, Yeon Hee Park, Keun Seok Lee, Yee Soo Chae, Binghe Xu, Xiaojia Wang, Seock-Ah Im, Wei Li, Yen-Shen Lu, Cecilia Orbegoso Aguilar, Soichiro Nishijima, Yuji Nishiyama, Masahiro Sugihara, Shanu Modi, Junji Tsurutani
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast cancer (Tokyo, Japan) 31 (5) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
K Nozawa, M Terada, M Onishi, Y Ozaki, T Takano, W Fakhouri, D Novick, J M Haro, L H Faris, T Kawaguchi, Y Tanizawa, Junji Tsurutani
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan. Breast cancer (Tokyo, Japan) (2023)
Hiromichi Matsuoka, Junji Tsurutani, Yasutaka Chiba, Yoshihiko Fujita, Kiyohiro Sakai, Takeshi Yoshida, Miki Nakura, Ryo Sakamoto, Chihiro Makimura, Yoichi Ohtake, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda, Tatsuya Okuno, Naoki Takegawa, Koji Haratani, Atsuko Koyama, Kazuto Nishio, Kazuhiko Nakagawa
Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study). The oncologist (2022)
Shigetoshi Nishihara, Toshimitsu Yamaoka, Fumihiro Ishikawa, Tohru Ohmori, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryo Manabe, Yuki Hasebe, Hironori Sagara, Hitoshi Yoshida, Junji Tsurutani
Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR -Activating Mutation. Cells 11 (14) (2022)
Norikazu Masuda, Tetsuhiro Yoshinami, Masahiko Ikeda, Makiko Mizutani, Miki Yamaguchi, Yoshifumi Komoike, Tsutomu Takashima, Katsuhide Yoshidome, Junji Tsurutani, Mitsuhiko Iwamoto, Fumie Fujisawa, Hiroyuki Yasojima, Jun Yamamura, Hirotaka Morishima, Fuminori Aki, Tomomi Yamada, Satoshi Morita, Takahiro Nakayama
Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214. Cancers 13 (17) (2021)
Bob T Li, Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai, Sophie Shifman, Hai-Yan Tu, Mackenzie L Myers, Chong-Rui Xu, Marissa Mattar, Inna Khodos, Megan Little, Besnik Qeriqi, Gregory Weitsman, Clare J Wilhem, Alshad S Lalani, Irmina Diala, Rachel A Freedman, Nancy U Lin, David B Solit, Michael F Berger, Paul R Barber, Tony Ng, Michael D Offin, James M Isbell, David R Jones, Helena A Yu, Sheeno Thyparambil, Wei-Li Liao, Anuja Bhalkikar, Fabiola Cecchi, David M Hyman, Jason S Lewis, Darren J Buonocore, Alan L Ho, Vicky Makker, Jorge S Reis-Filho, Pedram Razavi, Maria E Arcila, Mark G Kris, John T Poirier, Ronglai Shen, Junji Tsurutani, Gary A Ulaner, Elisa de Stanchina, Neal X Rosen, Charles M Rudin, Maurizio Scaltriti
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer discovery 10 (5) (2020)
Ryotaro Ohkuma, Erica Yada, Shumpei Ishikawa, Daisuke Komura, Hidenobu Ishizaki, Koji Tamada, Yutaro Kubota, Kazuyuki Hamada, Hiroo Ishida, Yuya Hirasawa, Hirotsugu Ariizumi, Etsuko Satoh, Midori Shida, Makoto Watanabe, Rie Onoue, Kiyohiro Ando, Junji Tsurutani, Kiyoshi Yoshimura, Takehiko Yokobori, Tetsuro Sasada, Takeshi Aoki, Masahiko Murakami, Tomoko Norose, Nobuyuki Ohike, Masafumi Takimoto, Masahiko Izumizaki, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. PloS one 15 (1) (2020)
Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T Li
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer discovery 10 (5) (2020)
Toshimitsu Yamaoka, Satoru Arata, Mayumi Homma, Tetsuya Homma, Sojiro Kusumoto, Koichi Ando, Ryou Manabe, Yasunari Kishino, Motoi Ohba, Junji Tsurutani, Masafumi Takimoto, Tohru Ohmori, Hironori Sagara
Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury. International journal of molecular sciences 20 (16) (2019)
Tsutomu Iwasa, Junji Tsurutani, Satomi Watanabe, Ryoji Kato, Yutaka Mizuno, Yasuyuki Kojima, Tsutomu Takashima, Nobuki Matsunami, Takashi Morimoto, Jun Yamamura, Shoichiro Ohtani, Yuko Tanabe, Tetsuhiro Yoshinami, Toshimi Takano, Yoshifumi Komoike, Kazuhiko Nakagawa
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer. BMC cancer 19 (1) (2019)
Junji Tsurutani, Yukinori Sakata, Toshiyuki Matsuoka
Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study. Breast cancer (Tokyo, Japan) 26 (2) (2018)
Kaori Nakatani, Toshimitsu Yamaoka, Motoi Ohba, Ken-Ichi Fujita, Satoru Arata, Sojiro Kusumoto, Iori Taki-Takemoto, Daisuke Kamei, Shinichi Iwai, Junji Tsurutani, Tohru Ohmori
KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR. Molecular cancer therapeutics 18 (1) (2018)
Naoki Takegawa, Yoshikane Nonagase, Kimio Yonesaka, Kazuko Sakai, Osamu Maenishi, Yusuke Ogitani, Takao Tamura, Kazuto Nishio, Kazuhiko Nakagawa, Junji Tsurutani
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. International journal of cancer 141 (8) (2017)